Funder: Patient-Centered Outcomes Research Institute
Due Dates (Anticipated): May 2026 (Letter of Intent) | August 2026 (Deferral Request) | September 2026 (Full Application)
Funding Amounts: Up to $22M direct costs total: $2M for feasibility phase (up to 1.5 years), $20M for full-scale study phase (up to 5 years); maximum project period 6.5 years.
Summary: Supports large, patient-centered randomized comparative effectiveness trials with a required feasibility phase, focused on major evidence gaps in healthcare decisions.
Key Information: This is a forecasted opportunity; all dates are projected and subject to PCORI updates.